Your browser doesn't support javascript.
Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection.
Chu, Victoria T; Schwartz, Noah G; Donnelly, Marisa A P; Chuey, Meagan R; Soto, Raymond; Yousaf, Anna R; Schmitt-Matzen, Emily N; Sleweon, Sadia; Ruffin, Jasmine; Thornburg, Natalie; Harcourt, Jennifer L; Tamin, Azaibi; Kim, Gimin; Folster, Jennifer M; Hughes, Laura J; Tong, Suxiang; Stringer, Ginger; Albanese, Bernadette A; Totten, Sarah E; Hudziec, Meghan M; Matzinger, Shannon R; Dietrich, Elizabeth A; Sheldon, Sarah W; Stous, Sarah; McDonald, Eric C; Austin, Brett; Beatty, Mark E; Staples, J Erin; Killerby, Marie E; Hsu, Christopher H; Tate, Jacqueline E; Kirking, Hannah L; Matanock, Almea.
  • Chu VT; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Schwartz NG; Epidemic Intelligence Service, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Donnelly MAP; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Chuey MR; Epidemic Intelligence Service, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Soto R; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Yousaf AR; Epidemic Intelligence Service, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Schmitt-Matzen EN; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Sleweon S; Epidemic Intelligence Service, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Ruffin J; County of San Diego Health and Human Services Agency, San Diego, California.
  • Thornburg N; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Harcourt JL; Epidemic Intelligence Service, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Tamin A; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Kim G; Epidemic Intelligence Service, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Folster JM; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Hughes LJ; Epidemic Intelligence Service, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Tong S; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Stringer G; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Albanese BA; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Totten SE; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Hudziec MM; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Matzinger SR; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Dietrich EA; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Sheldon SW; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Stous S; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • McDonald EC; Colorado Department of Public Health and Environment, Denver.
  • Austin B; Tri-County Health Department, Greenwood Village, Colorado.
  • Beatty ME; Colorado Department of Public Health and Environment, Denver.
  • Staples JE; Colorado Department of Public Health and Environment, Denver.
  • Killerby ME; Colorado Department of Public Health and Environment, Denver.
  • Hsu CH; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Tate JE; COVID-19 Response Team, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Kirking HL; County of San Diego Health and Human Services Agency, San Diego, California.
  • Matanock A; County of San Diego Health and Human Services Agency, San Diego, California.
JAMA Intern Med ; 182(7): 701-709, 2022 07 01.
Article in English | MEDLINE | ID: covidwho-1825745
ABSTRACT
Importance As self-collected home antigen tests become widely available, a better understanding of their performance during the course of SARS-CoV-2 infection is needed.

Objective:

To evaluate the diagnostic performance of home antigen tests compared with reverse transcription-polymerase chain reaction (RT-PCR) and viral culture by days from illness onset, as well as user acceptability. Design, Setting, and

Participants:

This prospective cohort study was conducted from January to May 2021 in San Diego County, California, and metropolitan Denver, Colorado. The convenience sample included adults and children with RT-PCR-confirmed infection who used self-collected home antigen tests for 15 days and underwent at least 1 nasopharyngeal swab for RT-PCR, viral culture, and sequencing. Exposures SARS-CoV-2 infection. Main Outcomes and

Measures:

The primary outcome was the daily sensitivity of home antigen tests to detect RT-PCR-confirmed cases. Secondary outcomes included the daily percentage of antigen test, RT-PCR, and viral culture results that were positive, and antigen test sensitivity compared with same-day RT-PCR and cultures. Antigen test use errors and acceptability were assessed for a subset of participants.

Results:

This study enrolled 225 persons with RT-PCR-confirmed infection (median [range] age, 29 [1-83] years; 117 female participants [52%]; 10 [4%] Asian, 6 [3%] Black or African American, 50 [22%] Hispanic or Latino, 3 [1%] Native Hawaiian or Other Pacific Islander, 145 [64%] White, and 11 [5%] multiracial individuals) who completed 3044 antigen tests and 642 nasopharyngeal swabs. Antigen test sensitivity was 50% (95% CI, 45%-55%) during the infectious period, 64% (95% CI, 56%-70%) compared with same-day RT-PCR, and 84% (95% CI, 75%-90%) compared with same-day cultures. Antigen test sensitivity peaked 4 days after illness onset at 77% (95% CI, 69%-83%). Antigen test sensitivity improved with a second antigen test 1 to 2 days later, particularly early in the infection. Six days after illness onset, antigen test result positivity was 61% (95% CI, 53%-68%). Almost all (216 [96%]) surveyed individuals reported that they would be more likely to get tested for SARS-CoV-2 infection if home antigen tests were available over the counter. Conclusions and Relevance The results of this cohort study of home antigen tests suggest that sensitivity for SARS-CoV-2 was moderate compared with RT-PCR and high compared with viral culture. The results also suggest that symptomatic individuals with an initial negative home antigen test result for SARS-CoV-2 infection should test again 1 to 2 days later because test sensitivity peaked several days after illness onset and improved with repeated testing.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Child / Female / Humans Language: English Journal: JAMA Intern Med Year: 2022 Document Type: Article Affiliation country: Jamainternmed.2022.1827

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Child / Female / Humans Language: English Journal: JAMA Intern Med Year: 2022 Document Type: Article Affiliation country: Jamainternmed.2022.1827